Clinical Reviews in Bone and Mineral Metabolism

, Volume 4, Issue 4, pp 277–290

The use of teriparatide and PTH(1–84) for the treatment of osteoporosis

Authors

    • Amgen Inc
    • Stanford University School of Medicine
  • Paul D. Miller
    • Colorado Center for Bone Research
    • University of Colorado School of Medicine
Article

DOI: 10.1385/BMM:4:4:277

Cite this article as:
Wagman, R.B. & Miller, P.D. Clinic Rev Bone Miner Metab (2006) 4: 277. doi:10.1385/BMM:4:4:277

Abstract

Different therapeutic formulations of parathyroid hormone (PTH) have been studied for the treatment of osteoporosis: synthetic teriparatide [hPTH(1–34)], reconstituted from lysophilized powder; recombinant human teriparatide [rhPTH(1–34)], which has been commercially available since 2002; and PTH(1–84), which is under review by the US Food and Drug Administration (FDA). Teriparatide has demonstrated vertebral and nonvertebral vertebral antifracture efficacy, increases in BMD and biochemical markers of bone turnover, the cornerstones of judging success with an osteoporosis agent. PTH (1–84) may be an alternative consideration for the treatment of both the prevention of the first vertebral fracture as well as the reduction in future vertebral fracture risk in postmenopausal women with existing vertebral fractures. It remains to be seen if there are therapeutic differences between the already approved teriparatide and yet-to-be-approved PTH(1–84).

Key Words

OsteoporosisteriparatidePTH(1–34)PTH (1–84)fracturebone mineral densitybiochemical markers of bone turnover

Copyright information

© Humana Press Inc. 2006